Probable Steps in Tumour Targeting
1.Blood injection (iv) to access all possible sites (is agent stable?) Note that direct injection is used for sphere treatment of limited hepatic disease 2. Extravasation into tumour space due to fenestrations (is agent small enough to fit thru gaps?) 3 . Diffusion down a concentration gradient into the intra-tumour space (is there retrograde convection?) 4 . Fixing to the tumour cell (or at least close enough for radiation therapy work)
Possible movement to inside the tumour cells (internalization)
Blood Flow to the Tumour
Nanoscale Engineering
Two items are needed to build a radiopharmaceutical(RP):
1. A physical/chemical entity which targets tumour cells and/or their associated molecules. This is the pharmaceutical.
2.
A radiolabel attached to the pharmaceutical so that imaging and therapy are possible. Adding this aspect generates the radiopharmaceutical. Note that non-radioactive therapy is also possible with some RP agents.
Methods and Limitations of Radiolabeling
Iodine labeling is one-step. If this value is exceeded in a murine tumour, then we have evidence of specific targeting. Absorbed dose rate is proportional to uncorrected uptake so that therapy applications are clear.
Two Formats for Biodistribution Data
We generally wish to show the organ uptake corrected for radio decay (% ID/gm The "Problem of Plenty"
1. There are multiple classes (types) of potential tumour targeting agents. These types are not mutually exclusive.
2. Each type may have an almost astronomical number of variants such as 20 1500 for an intact antibody.
3. Yet the number of patients for a clinical trial is limited; approximately 3% of available patients will volunteer for a cancer protocol.
Thus, some sort of pre-clinical selection process is needed. I propose a figure of merit (FOM) to separate one agent from another.
Evidence for tumor uptake to be a function of tumour mass
From both animal and clinical data sets, there is evidence that many tumours have uptake (u T ) that is a function of the tumour mass (m). Generally, the larger the tumour, the smaller the uptake. We expect that the relationship is similar to: IFOM predicts a finite optimal time; R is monotone increasing such that an optimal time cannot be determined for 5 cT84.66 cognates.
Size of lesion for best imaging:
IFOM predicts a m 2/3 dependence ; R goes approximately as m -1/3 such that R is optimal for the smallest lesions. This is absurd.
Radiolabel:
IFOM goes as exp( -lt) ; R is independent of label so all radionuclides are said to be equal for imaging. This is equally absurd.
Figures of Merit based on Biodistribution may not be Enough
It may be that the agent is "intercepted" by normal organs on its way to the tumour. In this case, the uptake of the lesion is reduced so that biodistribution values may not indicate the actual effectiveness of the tracer in the lesion. What else can we look at? Additional Strategies involved in TRT:
Conclusions Regarding Targeting Agents
Multiple classes of agents and variable labels make choices for imaging and therapy difficult. Because of immune response, smaller MW agents are currently being favored over larger entities.
Strategies are being developed to enhance uptake using blocking, stealth, multi-step and other techniques. Largely a "black magic" arena with little numerical understanding.
While now a standard B-cell lymphoma therapy, the method may be expanded to include non-radioactive agents to stop tumour growth. Requires large amounts of material.
Thank you for your attention ! To enhance uptake and control absorbed doses more directly, a 2-or 3-step procedure is done instead of the single step. Invented by Mears and Goodwin, the process is as follows:
1. Injection of an unlabeled agent against antigen "x" but thereby exposes a new antigen "y" on its surface. 2. Subsequent injection of a labeled agent targeted to "y". This material usually has a very low MW and clears rapidly. 2A. A clearing step, between 1 and 2, may also be used to remove unlabeled material and reduce the likelihood of complexes in the blood.
